###begin article-title 0
###xml 95 97 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Altered expression of T cell Immunoglobulin-Mucin (TIM) molecules in bronchoalveolar lavage CD4+ T cells in sarcoidosis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Activated T helper (Th)-1 pulmonary CD4+ cells and their mediators are essential for the inflammation and granulomatous process in sarcoidosis. Recently, T-cell immunoglobulin and mucin domain (TIM) molecules were suggested to be important regulators of immune function. In this study, we wanted to investigate whether TIM molecules could play a role in sarcoidosis.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 196 198 192 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 268 277 264 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 28) </italic>
###xml 298 305 294 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 8)</italic>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
We used real-time polymerase chain reaction to investigate the differential gene expression of TIM-1 and TIM-3 as well as a few Th1 and Th2 cytokines (IL-2, IFN-gamma, IL-4, IL-5 and IL-13) in CD4+ T cells isolated from bronchoalveolar lavage fluid (BALF) of patients (n = 28) and healthy controls (n = 8). Using flow cytometry, we were also able to analyse TIM-3 protein expression in 10 patients and 6 healthy controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 23 34 23 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p &lt; 0.05) </italic>
###xml 46 57 46 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p &lt; 0.05) </italic>
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 369 379 369 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p &lt; 0.05)</italic>
###xml 431 442 431 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p &lt; 0.01) </italic>
###xml 525 534 521 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p &lt; 0.05</italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
A decreased TIM-3 mRNA (p < 0.05) and protein (p < 0.05) expression was observed in patients, and the level of TIM-3 mRNA correlated negatively with the CD4/CD8 T cell ratio in BALF cells of patients. Compared to a distinct subgroup of patients i.e. those with Lofgren's syndrome, BALF CD4+ T cells from non- Lofgren's patients expressed decreased mRNA levels of TIM-1 (p < 0.05). mRNA expression of IL-2 was increased in patients (p < 0.01) and non-Lofgren's patients expressed significantly higher levels of IFN-gamma mRNA (p < 0.05) versus patients with Lofgren's syndrome.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
These findings are the first data on the expression of TIM-1 and TIM-3 molecules in sarcoidosis. The reduced TIM-3 expression in the lungs of patients may result in a defective T cell ability to control the Th1 immune response and could thus contribute to the pathogenesis of sarcoidosis. The down-regulated TIM-1 expression in non-Lofgren'spatients is in agreement with an exaggerated Th1 response in these patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 419 420 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
Sarcoidosis is a T helper (Th) 1-mediated inflammatory disease with unknown aetiology, characterized by the formation of noncaseating granulomas, and involving accumulations of macrophages and T cells, primarily affecting the lungs [1]. In pulmonary sarcoidosis, an acute onset usually indicates a self-limiting disease course, whereas an insidious onset may be followed by persistent disease with a risk for fibrosis [1]. An imbalance in the expression of Th1/Th2 cytokines by alveolar cells has been suggested to be of importance for the outcome of a pulmonary immune response in sarcoidosis [2-4]. Lofgren's syndrome is regarded as a distinct clinical group with an acute onset of disease with erythema nodosum (EN) and/or ankle arthritis, bilateral hilar lymphadenopathy (BHL), fever and with a characteristic favourable disease outcome, often with complete spontaneous resolution. In contrast, non-Lofgren's patients more often have an insidious onset of disease with symptoms such as dry cough, low grade fever, fatigue, shortness of breath and more pronounced chest radiographic changes.
###end p 11
###begin p 12
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 424 426 424 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
The human leukocyte antigen (HLA)-DRB1*0301 allele has been reported to be overrepresented in sarcoidosis patients with Lofgren's syndrome [5]. Additional studies have revealed a strong association between HLA-DRB1*0301 and remarkable expansions of CD4+ T cells expressing T-cell receptors using the AV2S3 gene segment in bronchoalveolar lavage fluid (BALF) of Scandinavian sarcoidosis patients [6,7]. The expansion of AV2S3+ cells at disease onset was found to correlate with a better prognosis, suggesting a protective role for these cells in sarcoidosis [8]. However, any functional role of these cells has not been determined.
###end p 12
###begin p 13
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 936 944 936 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1210 1212 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1244 1245 1244 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1246 1248 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1336 1338 1336 1338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1347 1349 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1453 1455 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1606 1608 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1687 1689 1687 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1777 1779 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1780 1782 1780 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 490 496 <span type="species:ncbi:9606">humans</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 981 986 <span type="species:ncbi:10090">mouse</span>
###xml 1461 1465 <span type="species:ncbi:10090">mice</span>
Recent investigations of mechanisms that regulate activation and function of CD4+ T cells have shown that T cell immunoglobulin -mucin (TIM) proteins are important regulators of immune function. TIM family members are type I transmembrane proteins, with extracellular immunoglobulin and mucin domains and intracellular domains of different lengths. TIMs are differentially expressed on Th1 and Th2 cells [9,10]. The TIM gene family includes eight genes in mice and three genes in human. In humans, the gene encoding the TIM-1 protein has been considered as an important atopy susceptibility gene and is associated with Th2 T cell responses [11], suggesting that TIM-1 controls critical regulatory pathways in the immune system. Studies on mice have indicated that TIM-1 is involved in T helper cell differentiation and suggested that the protein is a positive regulator of T cell activity [12,13]. Furthermore, blocking of TIM-1 during in vivo development of T-cell responses in a mouse model of asthma was followed by decreased Th2 immune responses and airway inflammation [14]. Another member of TIM family proteins is TIM-3, which in contrast to TIM-1 preferentially is expressed on fully differentiated CD4+ Th1 cells but not on Th2 cells [9,15]. The ligand for TIM-3 has been identified as galectin-9, with expression mostly on CD4+ T cells [16]. Galectin-9 has been shown to induce apoptosis of T cells via the calcium-calpain- caspase-1 pathway [17]. In mice, interference with the TIM-3-TIM-3-ligand binding resulted in hyperproliferation of Th1 cells with spontaneous production of Th1 cytokines [18], as well as macrophage activation and accelerated Th1-mediated autoimmunity [19]. Accumulating data suggest that TIM-3 negatively regulates Th1-type immune responses [16,18].
###end p 13
###begin p 14
###xml 111 113 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 507 509 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
In the current study we examined the mRNA expression of TIM-1 and TIM-3 as well as Th1 and Th2 cytokines in CD4+ T cells sorted by means of flow cytometry from BALF of patients with active sarcoidosis and healthy subjects. In addition using flow cytometry, the protein expression of TIMs on BALF and blood Tcells was investigated. The patients were stratified depending on whether they had Lofgren's syndrome or not. The expression of the same genes was also investigated in compartmentalized BALF CD4+AV2S3+ T cells from patients with lung restricted AV2S3 T cell expansions.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Study subjects
###end title 16
###begin p 17
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">Patients</span>
###xml 732 739 <span type="species:ncbi:9606">patient</span>
The study was performed on 47 patients with pulmonary sarcoidosis and 14 healthy controls (table 1). All patients, including both Lofgren's and non-Lofgren's patients, had an active, symtomatic disease and were consecutively included as they were referred for diagnostic purposes for the first time to the Division of Respiratory Medicine, Karolinska University Hospital, Stockholm, Sweden. Patients had a clinical picture in accordance with pulmonary sarcoidosis, as determined by symptoms (such as cough, shortness of breath and fatigue), chest radiography and pulmonary function tests, and the diagnosis was established using the criteria by the World Association of Sarcoidosis and other Granulomatous disorders (WASOG) [1]. No patient was on treatment with immunosuppressive drugs.
###end p 17
###begin p 18
BALF analysis and lung function parameters
###end p 18
###begin p 19
Data are shown as median (min-max)
###end p 19
###begin p 20
VC: Vital Capacity
###end p 20
###begin p 21
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
FEV1: Forced Expiratory Volume in the first second
###end p 21
###begin p 22
DLco: Diffusing capacity of the lung for carbon monoxide
###end p 22
###begin p 23
**p < 0.01 versus healthy controls
###end p 23
###begin p 24
*** p < 0.001 versus healthy controls
###end p 24
###begin p 25
###xml 24 31 <span type="species:ncbi:9606">patient</span>
dagger p < 0.05 between patient subgroups
###end p 25
###begin p 26
ND, not done
###end p 26
###begin p 27
1) Defined as at least three times higher than the corresponding median value in PBMCs from healthy controls i.e. >/= 10.5%.
###end p 27
###begin p 28
###xml 69 77 69 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 26)</italic>
###xml 97 105 97 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 21)</italic>
###xml 115 117 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
Patients were divided into two groups; those with Lofgren's syndrome (n = 26), and those without (n = 21). BALF CD4+ T cells were isolated from 28 of the patients; 13 with Lofgren's syndrome and 15 non-Lofgren's patients. FACS sorted BALF CD4+ T cells from 8 non-smoking healthy adults were included as controls.
###end p 28
###begin p 29
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 104 106 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 122 123 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 124 126 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 149 151 147 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 208 209 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 214 215 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 228 230 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 235 236 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 323 324 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 329 331 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 401 403 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 417 418 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 423 425 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
In addition, from 12 of the patients with lung restricted expansions of AV2S3+ T cells (>/= 10.5% of CD4+ cells in BALF) [6,20], we isolated BALF CD4+ T cells either expressing the TCR AV2S3 gene segment (CD4+AV2S3+) or not (CD4+ AV2S3-). All except one had Lofgren's syndrome. In order to obtain a sufficient number of CD4+AV2S3+ T cells, in all but three patients we had to choose to sort either CD4+ T cells or CD4+AV2S3+ T cells.
###end p 29
###begin p 30
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Finally, we analysed by flow cytometry TIM-1 and TIM-3 proteins on BALF and blood T cells of 10 patients (four with Lofgren's syndrome) and 6 healthy subjects, using antibodies that were made commercially available during the course of the study.
###end p 30
###begin p 31
All subjects gave their informed consent to participate in the study, and the local ethics committee, the Regional Ethical Review Board in Stockholm (ref. nr: 2005/1031-31) approved the study.
###end p 31
###begin title 32
Bronchoalveolar lavage (BAL)
###end title 32
###begin p 33
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
Bronchoalveolar lavage was performed as described [21]. Briefly, fibreoptic bronchoscopy was performed under local anaesthesia on patients. A flexible fiberoptic bronchoscope (OBF Type 1 TR; Olympus Optical Co., Japan) was passed transorally and wedged into the middle-lobe bronchus and sterile phosphate-buffered saline (PBS) solution at 37degreesC was instilled in five aliquots of 50 ml and immediately re-aspirated and collected in a siliconized plastic bottle that was kept on ice.
###end p 33
###begin p 34
The BAL fluids recovered were centrifugated at 400 g for 10 min at 4degreesC, to separate BAL cells from the supernatant. The cell pellet was resuspended in RPMI-1640 medium (Sigma-Aldrich, Irvin, UK) and the viability was determined by trypan blue exclusion. Cell differential counts were determined by May-Grunwald-Giemsa staining of cytopin slides.
###end p 34
###begin title 35
Flow cytometric analysis and isolation of cells
###end title 35
###begin p 36
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 155 157 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 218 223 <span type="species:ncbi:9606">human</span>
BALF CD4/CD8 T lymphocyte ratio and TCR AV2S3 expression in BALF cells was determined by FACS analysis using monoclonal antibodies (Mabs) against CD3+, CD4+ and CD8+ (Dako Cytomation Norden AB, Solna, Sweden) and anti-human TCR AV2S3 (clone F1) (Pierce Biotechnology, Rockford, USA), as previously described [22].
###end p 36
###begin p 37
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 375 377 375 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 398 400 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
For sorting, cells were stained with anti- CD4-Phycoerythrin (PE) (DAKO) and anti-TCR AV2S3-Flourescein isothiocyanate (FITC) (Pierce Biotechnology). The stained cells were sorted by FACSVantage (BD Biosciences, Montain View, California, USA). BALF cells were gated on lymphocytes and sorted into different populations; CD4+ T cells from patients and controls, as well as CD4+ AV2S3+ and CD4+ AV2S3- T cells from patients with lung accumulated T cells expressing the AV2S3 TCR gene segment. The purity of the sorted populations, which was determined by FACS, was 98% on average.
###end p 37
###begin p 38
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 189 191 189 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1001 1002 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1005 1006 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1012 1013 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1016 1018 1015 1017 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 293 298 <span type="species:ncbi:9606">human</span>
###xml 376 380 <span type="species:ncbi:9925">goat</span>
###xml 386 391 <span type="species:ncbi:10090">mouse</span>
###xml 444 449 <span type="species:ncbi:10090">mouse</span>
###xml 517 522 <span type="species:ncbi:9606">human</span>
###xml 699 704 <span type="species:ncbi:10090">Mouse</span>
###xml 733 738 <span type="species:ncbi:10090">mouse</span>
###xml 788 791 <span type="species:ncbi:10116">rat</span>
The analysis of TIM-1 and TIM-3 cell surface expression in blood and BALF CD4+ and CD8+ T cells was performed on BD FACSCanto II flow cytometer with FACSDiva software (BD Biosience). 1 x 106 BALF cells or 100 mul heparinized blood were surface stained with primary monoclonal antibody against human TIM-1 (R&D system, Minneapolis, Minnesota, USA), followed by APC- conjugated goat anti-mouse antibody. Cells were washed and blocked with normal mouse serum. Subsequently, cells were incubated for 20 minutes with anti-human CD3-pacific blue (BD Biosciences), CD4-APC H7 (BD Biosciences), CD8-PE-cy5 (BD Biosciences), AV2S3-FITC (Pierce Biotechnology) and TIM-3-PE (R&D system) monoclonal antibodies. Mouse IgG1-FITC (BD Biosciences), mouse IgG2b (Nordic Biosite AB, Stockholm, Sweden) and rat IgG2a (BD Biosciences) were used as isotype controls. The red blood cells were lysed after the end of incubations. Expression of cell surface markers was determined by flow cytometry after gating on either CD3+CD4+or CD3+CD8+ lymphocytes.
###end p 38
###begin title 39
Quantitative analysis of the gene expression by real-time polymerase chain reaction (PCR)
###end title 39
###begin p 40
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 290 292 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 318 320 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Total RNA was extracted and cDNA was synthesized. Gene expression was quantified by real-time PCR using ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), as described [23]. RNA specimens were analyzed in duplicate using primers and probes for beta-actin [23], TIM-1 and total TIM-3 [15] as well as the Assay-On-Demand products for IFN-gamma (Hs00174143_m1), IL-2 (Hs00174114_m1), IL-13 (Hs00174379_m1), IL-4 (Hs00929861_g1), IL-5 (Hs99999031-m1) and galectin-9 (Hs00247135-m1). The Assay-On-Demand products and universal master mix were commercially purchased (Applied Biosystems). All samples were run in duplicates and the mean values calculated.
###end p 40
###begin p 41
###xml 114 128 114 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;CT </sup>
For relative quantification of expression of each gene in BALF cells, the following arithmetic formula was used: 2-DeltaDeltaCT (Perkin-Elmer Instruction manual, 1997), where the amount of target gene was normalized to beta-actin (house-keeping gene) and the relative expression of a gene in BALF was calculated in relation to the mean value of target gene expression in the healthy control group.
###end p 41
###begin title 42
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen typing
###end title 42
###begin p 43
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
HLA class II (HLA-DR) typing was done on DNA by PCR amplification using sequence specific primers [24].
###end p 43
###begin title 44
Statistics
###end title 44
###begin p 45
###xml 506 515 506 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.05 </italic>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
Significance levels were calculated according to nonparametric tests, using Mann-Whitney U test for comparison between two groups or the Kruskal-Wallis test followed by Dunn's post-test for comparisons between groups. The non-parametric Wilcoxon matched pairs statistical test was used for calculation of statistical significances of TIM-3 expression between BAL and blood in patients and controls. Correlations between different parameters were determined with Spearman's rank correlation test. Values of p < 0.05 were regarded as significant. All statistical analyses were performed with Graphpad Prism 4.03 (Graphpad software Inc, San Diego, California, USA).
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
BALF analysis and lung function parameters
###end title 47
###begin p 48
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 189 196 <span type="species:ncbi:9606">patient</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
Table 1 shows the BALF cell characteristics and the results of pulmonary function tests in the patients and controls. Whereas BAL cell concentrations and percentages of lymphocytes in each patient subgroup compared to controls were increased, the percentages of macrophages were decreased in patients. There was also a tendency to increased BAL cell concentrations in non-Lofgren's patients versus Lofgren's patients. The forced expiratory volume in one second (FEV1) was lower in non-Lofgren's sarcoidosis patients than in Lofgren's patients.
###end p 48
###begin title 49
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4+ </sup>
TIM mRNA expression in CD4+ T cells
###end title 49
###begin p 50
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 358 367 358 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 15) </italic>
###xml 407 416 407 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 13) </italic>
###xml 417 425 417 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.03</italic>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 535 543 535 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.02</italic>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 249 256 <span type="species:ncbi:9606">patient</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
The mRNA expression of TIMs was investigated in FACS-sorted BALF CD4+ T cells. Using real time PCR, we found no significant differences in the mRNA levels of TIM-1 between patients and controls (figure 1a). However, analysing the gene expression in patient subgroups showed that there was a significant decrease in TIM-1 expression in non-Lofgren's patients (n = 15) versus patients with Lofgren's syndrome (n = 13) (p = 0.03; figure 1a). A significant reduction in TIM-3 mRNA expression was observed in patients compared to controls (p = 0.02; figure 1b). There was no difference in TIM-3 mRNA expression between Lofgren's and non-Lofgren's patients, but both subgroups showed significantly decreased levels of TIM-3 compared to controls (figure 1b).
###end p 50
###begin p 51
###xml 121 123 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 159 167 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 28)</italic>
###xml 231 239 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 13)</italic>
###xml 255 264 251 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 15) </italic>
###xml 294 302 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 8) </italic>
###xml 0 314 0 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The relative RNA transcript for a) TIM-1, b) TIM-3, c) IL-2, d) IFN-&#947;, e) IL-13 and f) galectin-9 (gal-9) in BALF CD4<sup>+ </sup>T cells of all sarcoidosis patients <italic>(n = 28)</italic>, including patient subgroups: patients with L&#246;fgren's syndrome <italic>(n = 13)</italic>, non-L&#246;fgren's <italic>(n = 15) </italic>patients and healthy controls <italic>(n = 8) </italic>was measured</bold>
###xml 408 418 404 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p = 0.02)</italic>
###xml 525 536 521 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p = 0.008)</italic>
###xml 598 608 594 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p = 0.03)</italic>
###xml 655 666 647 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p = 0.03) </italic>
###xml 767 788 759 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.05, ** p &lt; 0.01</italic>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 179 186 <span type="species:ncbi:9606">patient</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
The relative RNA transcript for a) TIM-1, b) TIM-3, c) IL-2, d) IFN-gamma, e) IL-13 and f) galectin-9 (gal-9) in BALF CD4+ T cells of all sarcoidosis patients (n = 28), including patient subgroups: patients with Lofgren's syndrome (n = 13), non-Lofgren's (n = 15) patients and healthy controls (n = 8) was measured. TIM-3 mRNA levels were significantly decreased in sarcoidosis patients compared to controls (p = 0.02), while the mRNA levels of IL-2 were significantly increased in sarcoidosis patients comparing to controls (p = 0.008). The relative TIM-1 mRNA levels were significantly decreased (p = 0.03), while IFN-gamma mRNA expression was elevated (p = 0.03) in non- Lofgren's patients compared to Lofgren's patients. Horizontal bars indicate median values. * p < 0.05, ** p < 0.01.
###end p 51
###begin title 52
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4+ </sup>
Cytokine mRNA expression in CD4+ T cells
###end title 52
###begin p 53
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 194 196 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 254 263 254 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.008</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 658 666 646 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.03</italic>
###xml 675 677 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 769 778 753 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(p = 0.03</italic>
###xml 787 789 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 282 289 <span type="species:ncbi:9606">patient</span>
###xml 449 456 <span type="species:ncbi:9606">patient</span>
###xml 535 542 <span type="species:ncbi:9606">patient</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
We also analyzed the expression of Th1 and Th2 cytokines in BALF CD4+ T cells obtained from patients and controls. There was a significant increase in the relative expression of IL-2 mRNA in CD4+ T cells from sarcoidosis patients compared with controls (p = 0.008; figure 1c). Both patient subgroups showed significantly increased levels of IL-2 mRNA as compared to controls. There was no significant difference in IFN-gamma expression in the whole patient group compared to controls, but when we investigated IFN-gamma mRNA levels in patient subgroups, a significantly increased IFN-gamma level was observed in non-Lofgren's compared to Lofgren's patients (p = 0.03; figure 1d). The mRNA level of IFN-gamma was also increased in non-Lofgren's patients versus controls (p = 0.03; figure 1d).
###end p 53
###begin p 54
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 159 161 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
We detected no difference in IL-13 mRNA transcripts between patients and controls (figure 1e). IL-4 and IL-5 mRNA expression could only be detected in BALF CD4+ T cells of two patients and one control (data not shown).
###end p 54
###begin title 55
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4+ </sup>
Galectin-9 mRNA expression in BALF CD4+ T cells
###end title 55
###begin p 56
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 311 313 311 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 521 523 521 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 537 544 <span type="species:ncbi:9606">patient</span>
It has been reported that the interaction between TIM-3 and its ligand, galectin-9, could downregulate Th1 responses [16]. Because of the decreased TIM-3 expression in BALF CD4+ T cells of patients, we also analyzed the levels of galectin-9 in these cells and found that the expression of galectin-9 in BALF CD4+ cells from patients was similar to that in healthy controls (figure 1f), suggesting a normal galectin-9 expression in sarcoidosis. We found no statistically differences in expression of galectin-9 in BALF CD4+ cells between patient subgroups.
###end p 56
###begin title 57
Correlation between TIM expression in BALF cells and BALF cellular parameters
###end title 57
###begin p 58
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 169 171 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 217 236 217 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r = -0.4, p = 0.035</italic>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
When investigating associations between TIM molecules and BALF cellular parameters in patients, TIM-3 mRNA levels correlated negatively with the ratio of CD4+ to the CD8+ T cells in the lungs of sarcoidosis patients (r = -0.4, p = 0.035; figure 2).
###end p 58
###begin p 59
###xml 84 114 84 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 28; r = -0.4, p = 0.035) </italic>
###xml 0 140 0 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The levels of TIM-3 mRNA correlated negatively with the ratio of CD4 to CD8 in BALF <italic>(n = 28; r = -0.4, p = 0.035) </italic>in the whole patient group</bold>
###xml 127 134 <span type="species:ncbi:9606">patient</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
The levels of TIM-3 mRNA correlated negatively with the ratio of CD4 to CD8 in BALF (n = 28; r = -0.4, p = 0.035) in the whole patient group. The correlation was analysed using Spearman's rank correlation test. Filled circles: Lofgren's patients; open circles: non- Lofgren's patients.
###end p 59
###begin title 60
Correlation between TIMs and cytokine expression in BALF cells
###end title 60
###begin p 61
###xml 135 173 131 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r = 0.83, p = 0.02; r = 0.68, p = 0.01</italic>
###xml 197 202 193 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a, b</xref>
###xml 274 276 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
The level of TIM-1 mRNA correlated positively with the level of IFN-gamma in control subjects and in patients with Lofgren's syndrome (r = 0.83, p = 0.02; r = 0.68, p = 0.01; respectively, figures 3a, b), while no correlation in non- Lofgren's patients was observed (figure 3c).
###end p 61
###begin p 62
###xml 74 76 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 83 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The mRNA level of TIM-1 correlated with the level of IFN-&#947; in BALF CD4<sup>+ </sup>T cells</bold>
###xml 163 191 155 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 8; r = 0.88, p = 0.02) </italic>
###xml 217 245 209 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 13; r = 0.68, p = 0.01)</italic>
###xml 311 319 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(n = 15)</italic>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
The mRNA level of TIM-1 correlated with the level of IFN-gamma in BALF CD4+ T cells. The level of TIM-1 and IFN-gamma correlated positively in a) healthy controls (n = 8; r = 0.88, p = 0.02) and b) Lofgren's patients (n = 13; r = 0.68, p = 0.01), while no correlation was observed in c) non- Lofgren's patients (n = 15). The correlation was analysed using Spearman's rank correlation test.
###end p 62
###begin title 63
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4+</sup>
###xml 9 11 9 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
CD4+AV2S3+ T cells versus CD4+AV2S3- T cells
###end title 63
###begin p 64
###xml 110 111 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 116 118 112 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 125 126 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 133 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 285 287 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 299 301 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 383 385 379 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 397 399 393 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
The mRNA expression of TIM-1, TIM-3, IL-2, IFN-gamma and IL-13 was evaluated and compared between isolated CD4+AV2S3+ and CD4+AV2S3- BALF T cells of patients with lung restricted AV2S3 T cell expansions (n = 12). No differences were detected in mRNA expression for these genes in AV2S3+ versus AV2S3- BALF T cells (data not shown). A tendency to a decreased IL-13 mRNA level in AV2S3+ versus AV2S3- T cells was found, however IL-13 mRNA was detected in cells from only 5 patients.
###end p 64
###begin title 65
Cell surface expression of TIM molecules
###end title 65
###begin p 66
###xml 229 231 229 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.03</italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 451 453 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 548 550 548 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 608 616 608 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.05</italic>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 361 368 <span type="species:ncbi:9606">patient</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
Using antibodies against human TIM-1 and TIM-3 and flow cytometry, we determined the expression levels of TIM-3 on BALF and blood T cells from patients (n = 10) and controls (n = 6). The relative number of TIM-3 positive BALF CD4+ T cells was significantly reduced in patients compared with controls (p = 0.03; figures 4, 5). No difference was observed between patient subgroups. There was no difference in the frequency of TIM-3- expressing blood CD4+ T cells between patients and controls. Both controls and patients had higher percentages of CD4+ cells expressing TIM-3 in BALF versus blood (in controls: p < 0.05, in patients: p < 0.01; figure 5).
###end p 66
###begin p 67
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 115 0 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Flow cytometric analysis of TIM-3 protein expression in CD3<sup>+</sup>CD4<sup>+ </sup>lymphocytes in bronchoalveolar lavage fluid (BALF)</bold>
###xml 200 207 <span type="species:ncbi:9606">patient</span>
Flow cytometric analysis of TIM-3 protein expression in CD3+CD4+ lymphocytes in bronchoalveolar lavage fluid (BALF). The histograms show isotype controls and TIM-3 staining in BALF of one sarcoidosis patient (a, c) and one healthy control (b, d). Figures show representative results from independent experiments.
###end p 67
###begin p 68
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 125 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Flow cytometric analysis of TIM-3 protein expression in CD3<sup>+</sup>CD4<sup>+ </sup>lymphocytes in bronchoalveolar lavage fluid (BALF) and blood</bold>
###xml 217 219 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 288 296 288 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.03</italic>
###xml 416 425 416 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.03)</italic>
###xml 496 517 496 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.05, ** p &lt; 0.01</italic>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
Flow cytometric analysis of TIM-3 protein expression in CD3+CD4+ lymphocytes in bronchoalveolar lavage fluid (BALF) and blood. TIM-3 cell surface staining on BALF cells showed a lower frequency of TIM-3 expressing CD4+ cells in patients with sarcoidosis (n = 10) versus controls (n = 6) (p = 0.03). A higher frequency of TIM-3 expressing cells was observed in BALF versus blood (in patients, p = 0.004; in controls, p = 0.03). The lines indicate T cell subpopulations from the same individual. * p < 0.05, ** p < 0.01.
###end p 68
###begin p 69
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 176 183 <span type="species:ncbi:9606">patient</span>
In addition, analysing the expression of TIM-3 in BALF and blood CD8+ T cells, we found no statistically significant difference either between patients and controls or between patient subgroups (data not shown).
###end p 69
###begin p 70
###xml 48 56 <span type="species:ncbi:9606">patients</span>
TIM-1 was not detectable on T cells from either patients or controls.
###end p 70
###begin title 71
Discussion
###end title 71
###begin p 72
###xml 85 87 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
In this study, we demonstrate a decreased mRNA and protein level of TIM-3 in BALF CD4+ T cells of sarcoidosis patients with active disease, while IL-2 mRNA expression was elevated. In comparison to Lofgren's patients, patients without Lofgren's syndrome had reduced TIM-1 mRNA levels, whereas the IFN-gamma mRNA level was increased.
###end p 72
###begin p 73
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 491 493 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 627 629 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
The investigation of CD4+ T cell clones from cerebral spinal fluid (CSF) of patients with MS (a Th1-mediated disease) and control subjects showed that TIM-3 expression was down-regulated in MS [25]. Indeed, these clones secreted significantly higher amounts of IFN-gamma, but expressed reduced levels of TIM-3 mRNA compared to clones from healthy subjects. By using small inhibitory (si) RNA, to knock down TIM-3 expression, increased T-cell proliferation and IFN-gamma secretion was found [25]. Thus, a down-regulation of TIM-3 has been considered as an essential T-cell defect to control inflammation in diseases such as MS [25].
###end p 73
###begin p 74
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 115 117 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 261 263 261 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 327 329 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 408 410 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 453 455 453 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 524 526 524 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 537 539 537 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1070 1072 1070 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
###xml 1013 1020 <span type="species:ncbi:9606">patient</span>
###xml 1109 1116 <span type="species:ncbi:9606">patient</span>
Sarcoidosis is a Th1-mediated disease with accumulated CD4+ T cells in the lungs resulting in an increased BALF CD4+ to CD8+ T cell ratio, which has become a clinically important marker of sarcoidosis [1]. The observed reduction of TIM-3 mRNA levels in BALF CD4+ T cells of patients was associated with an increased CD4+ to CD8+ ratio in the lungs of patients, implying that a reduced TIM-3 expression on CD4+ BALF T cells may lead to more intensive CD4+ T cell accumulation in the lungs. The down-regulation of TIM-3 on CD4+ but not CD8+ T cells, as analysed by flow cytometry, may allow Th1 cells to escape galectin-9- induced cell-death, which is consistent with previous results from our group demonstrating that BALF lymphocytes from sarcoidosis patients displayed a non-apoptotic morphology and seemed to be resistant to apoptosis [26]. The fact that there was no difference in TIM-3 expression between Lofgren's and non- Lofgren's patients is also in line with the almost identical CD4/CD8 ratios in these patient subgroups, suggesting a similar disability of CD4+ T cells to undergo apoptosis in both patient subgroups.
###end p 74
###begin p 75
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
The decreased TIM-3 expression could hypothetically be caused by a genetic defect that leads to lower expression of TIM-3 on lung T cells in sarcoidosis patients. This notion may be supported by the association of genetic polymorphisms in human TIM-3 with susceptibility to the autoimmune disease rheumatoid arthritis (RA) [27]. We found no association between HLA-DRB1*0301, known to correlate with a better prognosis in sarcoidosis, and TIM-3 expression.
###end p 75
###begin p 76
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 383 390 <span type="species:ncbi:9606">patient</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
The recently identified Th-17 cells, which are highly pathogenic and implied to be involved in the development of various human autoimmune diseases, have also been shown to express low levels of TIM-3 relative to Th1 cells [28]. In addition, analysing the expression of the TIM-3 ligand, galectin-9, in CD4+ cells showed no difference either between patients and controls or between patient subgroups, suggesting TIM-3 as a key factor involved in the uncontrolled Th1 response in the lungs of patients.
###end p 76
###begin p 77
###xml 96 98 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Furthermore, in both controls and patients, we found a higher percentage of TIM-3-expressing CD4+ T cells in BALF versus blood, suggesting more pronounced regulatory mechanisms to be executed by TIM-3 in the BALF compartment compared with the blood.
###end p 77
###begin p 78
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1168 1170 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1332 1334 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1580 1582 1572 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 179 186 <span type="species:ncbi:9606">patient</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 704 712 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
###xml 803 811 <span type="species:ncbi:9606">patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
###xml 1294 1302 <span type="species:ncbi:9606">patients</span>
###xml 1403 1410 <span type="species:ncbi:9606">patient</span>
###xml 1461 1469 <span type="species:ncbi:9606">patients</span>
Our patient group includes a large number of patients with Lofgren's syndrome, which is a rather common disease presentation in Sweden, enabling separate studies of this distinct patient group. However, patients with non-Lofgren's phenotype may be more representative for global sarcoidosis patients. In sharp contrast to patients with Lofgren's syndrome, who usually have a very good prognosis with a high rate of spontaneous disease resolution, Swedish non-Lofgren's patients tend to have a non-resolving disease course (own observation). This has also been demonstrated in numerous studies from different countries, reviewed in [1]. As we recently reported, the Th1 response in the lungs of Lofgren's patients is decreased compared to non-Lofgren's patients [23]. In our present study, non-Lofgren's patients had a relatively increased IFN-gamma and a reduced TIM-1 mRNA level compared to Lofgren's patients. The differences in TIM-1 expression may be related to differences in Th1/Th2 profiles. Umetsu et al showed that TIM-1 expression is highly increased on newly activated cells, but with time Th1 cells lose its expression, while it is sustained on Th2 cells [13]. Thus, the down-regulated TIM-1 expression in non-Lofgren's patients goes well with the exaggerated Th1 response in these patients as also previously reported [23]. The reason why there is no difference in TIM-3 expression between patient subgroups despite higher IFN-gamma in non-Lofgren patients could be that, even if TIM-3 is a marker of Th1 cells, there is not a strict correlation between the total CD4+ cell mRNA expression of IFN-gamma and the mRNA expression of TIM-3 and/or frequency of TIM-3 expressing cells.
###end p 78
###begin p 79
###xml 190 192 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Similarly, studies on CSF mononuclear cells obtained from patients with MS revealed that higher mRNA expression of TIM-1 associated with clinical remissions and low expression of IFN-gamma [15], which could be due to the regulatory role of TIM-1 in inflammation.
###end p 79
###begin p 80
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 107 114 <span type="species:ncbi:9606">patient</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
In this study we could not find any differences in expression of the Th2 associated cytokine IL-13 between patient subgroups, and IL-4 and IL-5 were not detectable. However, we previously observed an exaggerated Th1 immune response in non- Lofgren's patients versus Lofgren's patients [23]. The possible role of Th2 cells in the lungs of Lofgren's patients is an unexplored area that needs to be further investigated.
###end p 80
###begin p 81
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 98 100 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 177 179 177 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 516 518 516 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 535 537 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 706 708 706 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
The expansion of AV2S3+ T cells in the lungs of HLA-DRB1*0301 positive patients implies that AV2S3+ T cells have been selected by interaction with a specific antigen [29]. AV2S3+ CD4+ lung T cells express activation markers [30] and high numbers of these cells correlate with disease activity and a better prognosis [31], which indicates a protective roll for this particular T cell subset [8]. Our recent observation of reduced expression of regulatory T cell associated molecules, CD25 [30] and FOXP3 [32] in AV2S3+ compared to AV2S3- cells suggests an effector rather than regulatory function for these cells. However, in this study we found no differences in either TIMs or cytokine expression in AV2S3+ BALF T cells. Further investigations are needed to clarify the exact function of these cells in sarcoidosis.
###end p 81
###begin p 82
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Strong correlations were observed between TIM-1 molecule mRNA expression and IFN-gamma mRNA levels in Lofgren's patients and controls, but not in non-Lofgren's patients. This is in line with an imbalanced pulmonary inflammation especially in non-Lofgren's patients.
###end p 82
###begin title 83
Conclusion
###end title 83
###begin p 84
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 260 265 <span type="species:ncbi:9606">human</span>
###xml 483 491 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
We demonstrate here a decreased mRNA and protein expression of TIM-3 in the BALF CD4+ T cells of sarcoidosis patients versus controls and decreased mRNA expression of TIM-1 in non-Lofgren's patiens versus Lofgren's patients (figure 6) [33]. Further studies on human TIM-3 polymorphisms and function in sarcoidosis may provide us with knowledge to further explain the pathogenesis of the disease. The reduced TIM-1 expression together with increased IFN-gamma levels in non-Lofgren's patients may relate to the more pronounced inflammatory reaction in these patients. Collectively, the reduced TIM-3 expression on Th1 cells in inflammatory sites may represent a T cell defect to control the Th1 response, which might contribute to the accumulation of inflammatory cells in the lungs and the pathogenesis of sarcoidosis.
###end p 84
###begin p 85
###xml 0 157 0 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hypothetical model of inflammatory reactions in sarcoidosis, comparing the immune response in the lungs of patients with L&#246;fgren's syndrome and those without</bold>
###xml 354 356 354 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 565 572 <span type="species:ncbi:9606">patient</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
Hypothetical model of inflammatory reactions in sarcoidosis, comparing the immune response in the lungs of patients with Lofgren's syndrome and those without. The triggering event is the presentation of an (unknown) antigen by antigen-presenting cells (APC) to T cells. In the lungs of patients, there are fewer regulatory T cells, as well as a lower CD4+ T cell expression of TIM-3, compared to healthy controls. Both these factors may contribute to the characteristic Th1-type inflammation. Differences in the exact type of antigen(s) presented in the respective patient subgroups, as well as antigen clearance or persistence, may contribute to the enhanced Th1 response seen in non-Lofgren's patients, which is associated with a lower CD4+ T cell TIM-1 expression compared to Lofgren's patients. Markers indicated in bold are those included in the present study, for the others see [22,31] and [32].
###end p 85
###begin title 86
Competing interests
###end title 86
###begin p 87
The authors declare that they have no competing interests.
###end p 87
###begin title 88
Authors' contributions
###end title 88
###begin p 89
FI participated in the design of the study and performed the practical lab works, the statistical analysis and wrote the manuscript. JW participated in the design of study and helped to draft the manuscript. BD helped in the flow cytometry analysis. MK and TO carried out the design and optimising of TIMs probes and primers. AE participated in the design of study and helped to draft the manuscript. JG conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors have read and approved the final manuscript.
###end p 89
###begin title 90
Acknowledgements
###end title 90
###begin p 91
###xml 40 46 <span type="species:ncbi:283025">Gunnel</span>
###xml 227 232 <span type="species:ncbi:50733">Oscar</span>
The authors thank Ms Margitha Dahl, Mrs Gunnel de Forest and Mrs Helene Blomquist for their technical assistance. The study was supported by grants from the Swedish Heart Lung Foundation, the Swedish Research Council, the King Oscar II Jubilee Foundation, the Mats Kleberg Foundation, the Torsten and Ragnar Soderberg Foundation, the American Thoracic Society/Foundation for Sarcoidosis Research, the Stockholm County Council and Karolinska Institutet, that were distributed to Johan Grunewald, Anders Eklund and Jan Wahlstrom and were important for the study design, data collection, analysis and interpretation of data.
###end p 91
###begin article-title 92
Statement on sarcoidosis
###end article-title 92
###begin article-title 93
Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation
###end article-title 93
###begin article-title 94
Sarcoidosis: immunopathogenetic concepts and their clinical application
###end article-title 94
###begin article-title 95
Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis
###end article-title 95
###begin article-title 96
###xml 46 54 <span type="species:ncbi:9606">patients</span>
HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis
###end article-title 96
###begin article-title 97
###xml 136 144 <span type="species:ncbi:9606">patients</span>
T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients
###end article-title 97
###begin article-title 98
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Lung restricted T cell receptor AV2S3+ CD4+ T cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation
###end article-title 98
###begin article-title 99
Lung T-helper cells expressing T-cell receptor AV2S3 associate with clinical features of pulmonary sarcoidosis
###end article-title 99
###begin article-title 100
The TIM gene family: emerging roles in immunity and disease
###end article-title 100
###begin article-title 101
The TIM gene family regulates autoimmune and allergic diseases
###end article-title 101
###begin article-title 102
TIM-1, a novel allergy and asthma susceptibility gene
###end article-title 102
###begin article-title 103
T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation
###end article-title 103
###begin article-title 104
TIM-1 induces T cell activation and inhibits the development of peripheral tolerance
###end article-title 104
###begin article-title 105
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma
###end article-title 105
###begin article-title 106
###xml 110 115 <span type="species:ncbi:9606">human</span>
T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosi
###end article-title 106
###begin article-title 107
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
###end article-title 107
###begin article-title 108
Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway
###end article-title 108
###begin article-title 109
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
###end article-title 109
###begin article-title 110
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
###end article-title 110
###begin article-title 111
T-cell expansions in healthy individuals
###end article-title 111
###begin article-title 112
Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis
###end article-title 112
###begin article-title 113
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Selective CD8+ T cells accumulate in the lungs of patients with allergic asthma after allergen bronchoprovocation
###end article-title 113
###begin article-title 114
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis
###end article-title 114
###begin article-title 115
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
###end article-title 115
###begin article-title 116
Dysregulated T cell expression of TIM3 in multiple sclerosis
###end article-title 116
###begin article-title 117
Apoptosis resistant bronchoalveolar lavage (BAL) fluid lymphocytes in sarcoidosis
###end article-title 117
###begin article-title 118
The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis
###end article-title 118
###begin article-title 119
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis
###end article-title 119
###begin article-title 120
###xml 151 159 <span type="species:ncbi:9606">patients</span>
Restricted usage of T cell receptor V alpha/J alpha gene segments with different nucleotide but identical amino acid sequences in HLA-DR3+ sarcoidosis patients
###end article-title 120
###begin article-title 121
Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis
###end article-title 121
###begin article-title 122
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Markers of activity in clinically recovered human leukocyte antigen-DR17-positive sarcoidosis patients
###end article-title 122
###begin article-title 123
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis
###end article-title 123
###begin article-title 124
Role of CD4+ T cells in sarcoidosis
###end article-title 124

